Wer kennt Genesis Technology Group ( GTEC )? - 500 Beiträge pro Seite

[RudiDutschke]

Werden die in der BRD gehandelt? Wenn ja , wie ist die WKN? Vielen Dank, schönen Tag noch

[miura]

moin Rudi

Werden nur in den USA gehandelt. WKN ist 931506.


Gruß
miura

[RudiDutschke]

Danke! Weisst du mehr über die Aktie? Soll ja ein kommender Highflyer sein, obwohl mensch ja vorsichtig sein muss mit solchen Aussagen. Grüsse Rudi

[miura]

Nee Rudi weiss nichts darüber, bin im Moment auch etwas im
Streß, schau mir die Sache heut abend mal an.

miura

[JavierOxtoa]

wieder ein schöner Push - wieder hat NITE da höchste Bid - es scheinen also ConSors-Käufer unterwegs zu sein.

Viel Glück - wir bestimmt bis 1$ laufen



Javi

[miura]

Hi Javi alter Schwede, was machst du eigentlich wenn
dein Probe-Abo abläuft ? Ich kann dich aber beruhigen.
Bei fast allen OTC Aktien macht NITE den höchsten Umsatz.
Und weißt du warum ? Der Bundestag hat aufgrund der amerikanischen
Konjunktur und wegen der Solidartät zu Stützungskäufen
aufgerufen. Da es Consors auch nicht besonders gut geht,
kauft ganz Deutschland jetzt die OTC über Consors auf.

miura

[RudiDutschke]

SPECIAL ALERT: Genesis Technology Group, Inc (OTC BB: GTEC)
November 2001


REASONS TO BUY GTEC

1.
Recently acquired 80 % ownership
in Shanghai G-Choice Science and
Technology Development
Company, LTD.- anticipated annual
revenues of $25- $30 million, this
year (2001), and profitable.
2.
G-Choice has exclusive distribution
rights for Intel and AMD CPUs in the
eastern part of China and for
Cyrix`s CPU in Shanghai. A
population of over 300 million
people.
3.
G-Choice`s sales in year 2000 were
$13.8 million, with $380,000 in
pre-tax net income (audited). In
the first 6 months of 2001,
G-Choice generated approximately
$11.7 million in sales. Management
expects the company to generate
$25-$30 million in annualized sales
by the end of this calendar year
(2001), and profitable.
4.
Recently Acquired Propamedia,
Inc., a streaming media company -
anticipated annual revenues of
about $3 million.
5.
Profitable company with strong
recurring revenue streams. Total
annual revenues expected to be
over $40 million by close of fiscal
2002.

SYMBOL:
GTEC
SHARES OUTSTANDING:
23mm
FLOAT (est.):
3mm
52 WEEK HIGH/LOW:
.51 - .02
SHORT TERM PRICE PROJ.:
$3.00
12 MONTH PRICE PROJ.:
$8.00




6.
Biotechnology subsidiary,
Biosystems Technologies Inc.,
negotiating exclusive distribution
rights for HIV/AIDS and Hepatitis
products in China.
7.
The Company is poised to
capitalize on the anticipated
economic explosion from China’s
entrance into the World Trade
Organization.
8.
New Interactive Direct Marketing
subsidiary, eSpectus Systems,
Inc. entering multibillion dollar
direct email market.
9.
New management team with
proven track record of business
success.
10.
Potential company spin-offs mean
shareholders gain stock in
additional companies.



INVESTMENT SUMMARY

When we consider GTEC, we must understand the business model and huge potential in
the Company’s valuation. GTEC develops, invests in, and operates high technology
related companies in the US, China, Taiwan, Hong Kong and Singapore. GTEC’s strategy
includes the internal development and operation of subsidiaries within the Company`s
corporate family, as well as investment in other high technology companies directly, and
through other venture capital arrangements. The Company`s strategy also envisions and
promotes opportunities for synergistic business relationships among all of the companies
within its family.

We believe the Company story will get a lot of attention in the investment community in
the coming months, as China joins the WTO. GTEC is a brand-new publicly trading
company via a reverse/merger with Newagecities.com, Inc. (NACT). The Company’s
mission is to accelerate the success of technology companies by acquisition and
development as evidenced by GTEC’s 2 recent acquisitions. GTEC has been growing at
an exciting rate and the foundation has been laid for spectacular growth in its earnings
and sales in the coming quarters. In a world in which ‘tech companies are losing money’
lurks around every corner of the market, it’s refreshing to find a technology company
that offers real success for growth in revenues and earnings.

China`s pending entry into the World Trade Organization (WTO) will generate enormous
opportunities within the service sector and give impetus to the country`s already robust
economic growth. The agreement on China`s WTO entry paves the way for China to join
the world trade body and opens up China`s economy to more foreign trade and
investment in sectors ranging from banking and automobiles to telecommunications and
IT services and products.

A recent survey by the Ministry of the Information Industry showed China`s IT industry
is robust, in sharp contrast to the slowdown in the growth of the world`s IT industry.
Statistics show that the sales volume of IT products for the past six months has
reached 356.1 billion yuan (US$43 billion) nationwide, up 28.3 percent over the same
period for the previous year. Registered Internet users have exceeded 26 million in the
country, an average annual increase of 25 percent. It is estimated that China will spend
one trillion yuan (US$120 billion) over the next five years to spur its information industry,
according to a meeting of Ministry of Information Industry held in Beijing on October 6,
2001. China`s information industry is to develop steadily, with its value added accounting
for seven percent of the nation`s gross domestic product by the year 2005, said sources
from the ministry. Through 2005, the information industry will become a major pillar
industry of the country. The Chinese government will make great efforts to push forward
and give priority to the application of information technology as a way of boosting
economic and social development.

Recently, GTEC’s subsidiary, entered into a distribution agreement with Intel Corporation
(INTC), Cyrix and Advanced Micro Devices, Inc. (AMD). Under the terms of the
agreement, GTEC’s subsidiary has exclusive distribution rights for Intel CPU and AMD
CPUs in the eastern part of China. GTEC has also been awarded the exclusive
distribution rights for Cyrix`s CPU in Shanghai. The Eastern part of China is believed to
have the most dynamic economy in the greater China marketplace.


VALUATION

A penny stock with multi-dollar potential: trading today for about 50 cents per share,
but in our opinion, has long-term potential for huge gains. The stock may be one of the
year`s BIG surprises, making its current status as an undiscovered stock a rare timing
opportunity for investors. Don`t overlook this one! We not only consider GTEC an
attractive "Emerging Growth Company," in our opinion, but also a "Value Stock" in view
of its revenues and earnings its current price is about $0.50 per share. We believe that
GTEC has targeted a creative niche in a hot sector.

One way to value a company is to look at its peers in the industry. One public
company listed on the OTCBB is pretty much in the same line of business as GTEC.
It is the Hartcourt Companies, Inc. (OTCBB: HRCT) that has about $43.5 million
market cap with only $10 million in annualized revenues and losing money. Even if
GTEC were to trade at the same market cap as HRCT, GTEC would then be valued
at $1.90 per share. If the stock trades to its peer’s valuation ratios, such as PE
and price to sales ratios, GTEC should be valued at about $6 per share. HRCT has
a HUGE following on Raging Bull (over 165,000 messages). GTEC has virtually NONE
(slightly over 100 posts). In our opinion UNDERVALUED AND OVERLOOKED.

The GTEC acquisition/spin-off schedule in 2002 should add a considerable number
of technology companies. According to management, this will bring the projected
revenue of GTEC by fiscal 2003 to $75 million and net income of $12.4 million or
earnings per share of $0.41 on the basis of 30 million shares outstanding (GTEC
intends to acquire other business’s by issuing restricted stock). If GTEC were to
trade in the marketplace at 15 times earnings, then this would value GTEC at
$6.15 per share. If GTEC were to trade in the marketplace at 3 times sales, this
would value GTEC at $7.50 per share. (HRCT trades today at about 4.5 times
annualized sales).


SUMMARY

We believe GTEC is well positioned to take advantage of the changes in the
technology industry. We believe these changes are still in their earliest stages,
affecting primarily the small technology companies to date. In other words, we
believe GTEC is situated nicely to ride out the slowing domestic economy. In our
opinion, we don`t see much downside for GTEC that is traded around $0.50 per
share.

[GuenterNetzer]

@Rudi

Wie kommst Du bei dem Namen darauf, zu zocken? Na egal. GTEC sind bekannt, werden derzeit per mail gepusht. Habe am Montag abend über Quelle aus USA erfahren, daß der Laden besser als sein Ruf ist. Mehr weiß ich auch nicht.

Bester Gruß

GN

[Moneymonster]

GENESIS TECHNOLOGY INC (GTEC)
11/08/2001 15:38:46 Eastern Time
Exchange OTC BB Volume 987500
Last 0.5800 Change -0.1100
Bid 0.5700 Bidsize 25
Ask 0.5900 Asksize 25
High 0.7100 Low 0.5400

oder????

Moneymonster

[GuenterNetzer]

@Moneymonster

bei den hohen Umsätzen sollte man fast wieder einsteigen. Gestern war mir der stock noch zu teuer. Steht schon länger auf meiner Watchlist. Habe allerdings noch nicht zu Ende recherchiert. Hast Du Infos?

Gruß

GN

[RudiDutschke]

Guten Morgen,

About Genesis Technology Group, Inc.

The mission of Genesis Technology Group, Inc. is to accelerate the success of
technology companies by acquisition and development. The Company develops,
invests in, and operates technology related companies in the US, China, Taiwan,
Hong Kong and Singapore. The Company strategy includes the internal development
and operation of subsidiaries within the Company corporate family, as well as
investment in other technology companies directly, and through other venture
capital arrangements. The Company strategy also envisions and promotes
opportunities for synergistic business relationships among all of the companies
within its family. For more information on the company, please visit
http://www.genesis-technology.net


http://chart.bigcharts.com/custom/freerealtime-com/chart.asp…

http://www.tscn.com/frti/GR-R-GTEC-1217815-0-1-0-260-400-211…

[Moneymonster]

@GuenterNetzer
http://www.stockhouse.com/comp_info.asp?symbol=GTEC&table=li…

Moneymonster

[Moneymonster]

Genesis Technology Group, Inc.`s Subsidiary Signs Distribution Agreement For Rapid HIV Test Kit With Pacific Biotech Company, Limited


WEST PALM BEACH, FL, Nov 08, 2001 (INTERNET WIRE via COMTEX) -- Genesis
Technology Group, Inc. (OTCBB: GTEC) announced today that its subsidiary,
Biosystems Technologies, Inc., has entered into a distribution agreement for a
Rapid HIV Test Kit with Pacific Biotech Company, Limited. Under the terms of the
agreement, Biosystems Technologies has the exclusive distribution rights for the
HIV Dipstick Kit in China.

The HIV Dipstick Kit was originally developed by the Program for Appropriate
Technology in Health (www.path.org). The HIV Dipstick is a rapid, inexpensive
method for the detection of antibodies to HIV-1 and HIV-2. The cost per test for
manufacturers in developing countries can be less than US$0.50 when purchased in
quantity, a price far lower than the cost of other commercially available rapid
tests. The test takes approximately 30 minutes to perform and requires no
special equipment, no special technical training and no refrigeration. The HIV
dipstick can be used in various settings including: primary health services such
as family planning or maternal child health clinics, particularly in rural areas
where laboratory facilities are not available; lower- to medium-volume blood
banks in developing countries; field testing in military or refugee camps;
medical research in HIV/AIDS; epidemiological field surveillance; and as a
diagnostic tool as part of an established algorithm using two or more different
HIV tests. The HIV dipstick test has been evaluated in the laboratory as well as
under field conditions in the developing world using over 10,000 serum samples,
and has consistently demonstrated a sensitivity of over 99 percent, while
retaining a specificity of 98 percent or more. An independent evaluation by the
World Health Organization of the HIV-1 version of the test was completed in
1990. The dipstick was subsequently optimized for combined detection of HIV-1
and HIV-2 in 1992, and has now been evaluated in 17 different countries.

Biosystems Technologies has also signed a letter of intent with the Zixing
Division, of the Shanghai No.1 Biochemical & Pharmaceutical Company to
manufacture and distribute the HIV Dipstick Test Kit in China.

Mr. Jiye Fang, head of the Zixing Division indicated, "Like many other
countries, China is faced with a very serious epidemic of HIV/AIDS. This is a
large and growing epidemic that has the potential to move from where it is now,
in focused risk groups, to become a very widespread epidemic. International
health groups including the United Nations estimate 1.25 to 1.5 million Chinese
are infected with the AIDS virus; some Chinese scientists say the figure could
approach 3 million, but the Health Ministry in China has held to the official
estimate that 600,000 people were HIV-infected at the end of 2000. An
inexpensive, rapid and accurate HIV test kit will allow us to quickly screen
millions of people in order to control the spread of HIV/AIDS".

Dr. James Wang, President of Biosystems Technologies commented, "We have
examined many technologies for rapid HIV detection. We strongly believe that we
have found an excellent candidate to use in entering into the Chinese market.
This product is at a very reasonable price when we consider that many other
technologies cost $5 to $10 per test. The HIV Dipstick Test Kit requires no
special technical training, no extra equipment and needs no refrigeration,
therefore it is perfect for screening large populations in China where HIV/AIDS
is a growing concern. With the negotiation of technology transfer underway, we
can significantly reduce manufacturing costs for the kit in order to provide for
massive distribution of the HIV Dipstick kit in China in the near future. We are
optimistic about this newly formed venture and believe it could add
significantly to our bottom line for years to come".

About Genesis Technology Group, Inc.

The mission of Genesis Technology Group, Inc. is to accelerate the success of
technology companies by acquisition and development. The Company develops,
invests in, and operates technology related companies in the US, China, Taiwan,
Hong Kong and Singapore. The Company strategy includes the internal development
and operation of subsidiaries within the Company corporate family, as well as
investment in other technology companies directly, and through other venture
capital arrangements. The Company strategy also envisions and promotes
opportunities for synergistic business relationships among all of the companies
within its family. For more information on the company, please visit
www.genesis-technology.net.

About Biosystems Technologies, Inc.

Biosystems Technologies, Inc. is engaged in the commercialization, marketing and
distribution of biomedical products and technologies used to diagnose and treat
HIV/AIDS, cancer and other immune-related diseases. Biosystems Technologies is
harnessing the latest scientific discoveries to commercialize and market the
potential of proprietary technologies that will form the basis of a range of new
and potentially effective treatments for a variety of diseases. The company`s
Web site is available at www.biosystems-technologies.com.

About Pacific Biotech Company, Limited

Pacific Biotech, located in Bangkok, Thailand, manufactures high quality
diagnostic products to serve the healthcare market worldwide on an OEM basis and
on via its own brand. It has built a strong reputation for premium quality
product and superb customer service for over a decade. Their scientists research
new technologies everyday and inspect during every phase of operations to meet
world-class industrial standards. Quality hallmarks of Pacific Biotech products
and services meet the GMP manufacturing, Tai FDA compliance and ISO 9002. With
the strong support from the Board of Investment and National Science and
Technology Development Agency, Pacific Biotech is the most initial effort
between the government and its private sectors to promote the development of
indigenous biotechnology industry. The company`s Web site is available at
www.pacific-biotech.com/

About Shanghai No.1 Biochemical and Pharmaceutical Company

Shanghai No.1 Biochemical & Pharmaceutical Company (S1 BPC) has experienced 60
years of development. The company actively pursues a high production value,
high-tech development superiority and highly efficient management system to meet
the requirements of the intelligent economy era and the grand cycle of the
international economy. The company has been named the High-Tech Enterprise by
the Shanghai Municipal Government every year since 1994. It produces 3
categories of products, including biopharmaceuticals, chemical pharmaceuticals,
and Chinese traditional medicines (CTMs). The company operates with in three
main areas. Its core products consist of CTMs represented by the DANSHEN
products, and biopharmaceuticals represented by multi-peptides and genetic
products. Its core technologies include extraction and separation technology of
Chinese Herbs, synthesis of multi-peptides and purification of genetic
engineering products, and production technology of injections and freeze-dry
powders. Their core capabilities are in the area o modern commercialization of
high-tech biopharmaceutical products, commercial production of active
ingredients and finished goods. The company is a large-scale enterprise
consisting of 6 divisions and 1 Joint-Venture. S1 BPC occupies a space 77,964
square meters and is expanding to an additional 52,538 square meters.
Additionally, S1 BPC is renovating and upgrading its existing facilities. For
more information, please visit www.sbpc.com.cn/.

This announcement contains forward-looking statements that involve risks and
uncertainties, including those relating to the company`s ability to grow its
business and potential difficulties in bringing products to market in new areas,
and establishing working relationships with strategic partners. In addition,
biotechnology related products may require additional regulatory approval.
Actual results may differ materially from the results predicted and reported
results should not be considered as an indication of future performance. The
potential risks and uncertainties include, among others, the company`s limited
operating history, the limited financial resources, domestic or global economic
conditions, activities of competitors and the presence of new or additional
competition, and changes in Federal or State laws and conditions of equity
markets. More information about the potential factors that could affect the
company`s business and financial results is included in the company`s filings,
available via the Securities & Exchange Commission.



CONTACT: Dr. Ken Shenkman
Genesis Technology Group, Inc., West Palm Beach
561-835-6600


Copyright 2001 Internet Wire, All rights reserved.


Moneymonster

[mcdata]

Recent Events
Nov 6 Price hit new 52-week high ($0.74)
Location
1401 Johnson Ferry Rd., Suite 328 F-36
Marrieta, GA 30062
Phone: [phone]
Email: [e-mail]
Employees (last reported count): 3
watttttt nur 3 angestellte ????? geillllll